secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0000014272-22-000194
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99
---------------------------------------------------------------

- Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.
- GAAP EPS $0.75, Non-GAAP EPS $1.99; non-GAAP excludes amortization and acquired IPRD charges.
- In-line and new product portfolio grew 8% to $8.6B (13% ex-FX); Revlimid fell 28% to $2.4B.
- Completed Turning Point acquisition; FDA approved Sotyktu for plaque psoriasis in September.
- Adjusted 2022 GAAP EPS guidance; reaffirmed non-GAAP EPS guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/0000014272-22-000194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/bmy-20221025.htm
  HTML page:      https://secwatch.observer/filing/0000014272-22-000194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer